Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Bladder Cancer: early-phase trial registry
1 of 4 indexed Metastatic Bladder Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 1 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Metastatic Bladder Cancer: 4 US clinical trials tracked, 1 recruiting.
Metastatic Bladder Cancer is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Achieve Life Sciences, running 1 of these trials.
Enrollment posture brief
Registry condition metastatic-bladder-cancer
OPEN 1 | RECR 25% | LATE 0 | EARLY 3 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)
Metastatic Bladder Cancer lists 1 open slots (25% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Bladder Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Bladder Cancer is recruiting below its size-band peers.
1 of 4 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
Dana-Farber Cancer Institute
NCT06138561
A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer
Memorial Sloan Kettering Cancer Center
NCT02989584
A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer
Achieve Life Sciences
NCT01454089
Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies
Processa Pharmaceuticals
NCT02030067
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Bladder Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Bladder Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Bladder Cancer page
4 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Metastatic Bladder Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Achieve Life Sciences sponsors the most Metastatic Bladder Cancer trials on record, review their full trial history before evaluating a specific study. See Achieve Life Sciences's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Bladder Cancer condition card totals 4 registered trials; most-linked intervention Gemcitabine; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.